
Please try another search
Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and is in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany Spain and Thailand. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Name | Age | Since | Title |
---|---|---|---|
Wayne F. Pisano | 66 | 2018 | Independent Director |
David J. Drutz | 82 | 2011 | Independent Director |
Mitchel B. Sayare | 73 | 2010 | Independent Chairman |
John Petricciani | 85 | - | Member of Scientific Advisory Board |
Diane Kathryn Jorkasky | 69 | 2020 | Independent Director |
Richard James Whitley | 75 | - | Member of Scientific Advisory Board |
Philip L. Hodges | 52 | 2017 | Independent Director |
Klaus O. Schafer | 71 | 2012 | Independent Director |
John M. Gill | 69 | 2004 | Independent Director |
Vipin K. Garg | 63 | 2018 | President, CEO & Director |
Naga Chalasani | - | 2022 | Member of Nash Scientific Advisory Board |
Daniel J. Drucker | - | 2022 | Member of Obesity Scientific Advisory Board |
Samuel Klein | - | 2022 | Member of Obesity Scientific Advisory Board |
Mazen Noureddin | - | 2022 | Member of Nash Scientific Advisory Board |
Donna Ryan | - | 2022 | Member of Obesity Scientific Advisory Board |
Caroline M. Apovian | - | 2022 | Member of Obesity Scientific Advisory Board |
Louis J. Aronne | 66 | 2022 | Member of Obesity Scientific Advisory Board |
Juan Pablo Frias | - | 2022 | Member of Obesity Scientific Advisory Board |
Stephen A. Harrison | - | 2022 | Member of Nash Scientific Advisory Board |
Michael Charlton | - | 2022 | Member of Nash Scientific Advisory Board |
Robert F. Kushner | - | 2022 | Member of Obesity Scientific Advisory Board |
Rohit Loomba | - | 2022 | Member of Nash Scientific Advisory Board |
John M. Amatruda | 77 | 2022 | Member of Obesity Scientific Advisory Board |
Catherine Angell Sohn | 70 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review